Wnt Signaling Fuels Deadly Stomach Cancer Metastasis

Wnt Signaling Fuels Deadly Stomach Cancer Metastasis

Gastric cancer is among the leading killers worldwide. Yet, the exact mechanism enabling it to spread to distant organs has long baffled scientists. Now, researchers at Kanazawa University have uncovered a powerful and previously overlooked pathway. Their findings, published in Nature Communications (2026), reveal how Wnt signaling drives stomach cancer cells to remodel surrounding tissue — actively preparing distant organs for tumor colonization.

What Is Wnt Signaling in Gastric Cancer?

A Pathway Hijacked by Tumors

Wnt signaling is a fundamental biological pathway. Under normal conditions, it supports stem cell maintenance and tissue regeneration. However, gastric cancer cells exploit this pathway in a sinister way. Rather than relying on genetic mutations — as seen in colorectal cancer — stomach tumors activate Wnt signaling through external ligand stimulation. This distinction is critical. It means the tumor’s spread is not simply a genetic inevitability. Instead, it is an active, dynamic process that cancer cells initiate within their microenvironment.

Furthermore, this ligand-dependent activation means the tumor is constantly communicating with surrounding healthy tissue. Consequently, blocking this communication could become a viable therapeutic target.

How Cancer Cells Reshape Surrounding Tissue

Stromal Fibroblasts as Unwilling Accomplices

Using advanced mouse and organoid models, team leader Masanobu Oshima and colleagues investigated how gastric cancer spreads specifically to the liver. Their research demonstrates that tumor cells secrete Wnt ligands. These ligands then activate surrounding stromal fibroblasts — cells that normally maintain tissue structure. Once activated, these fibroblasts become cancer-associated fibroblasts (CAFs). As a result, they begin producing substances that actively support the tumor’s growth in distant organs.

H3: TGF-β and Wnt Signaling Work Together

Notably, Wnt signaling does not act alone. It cooperates with TGF-β signaling to activate these fibroblasts. Together, these two pathways amplify the tumor’s ability to remodel its surroundings. This cooperation makes the cancer especially aggressive — and also suggests that targeting either pathway could disrupt the metastatic process.

The Role of Hyaluronan in Metastatic Spread

Building a Supportive Niche for Cancer Cells

One of the study’s most striking revelations involves hyaluronan. Activated fibroblasts express the gene Has2, which produces hyaluronan — a large, sugar-like molecule that forms part of the extracellular matrix. Under normal circumstances, hyaluronan provides structural support to tissues. However, in a Wnt-activated tumor microenvironment, it serves a very different purpose.

Hyaluronan accumulates at metastatic sites, particularly in the liver. There, it creates a rich, supportive niche that allows incoming cancer cells to survive and establish new tumors. In short, stomach cancer cells do not simply travel to the liver and hope for the best. Instead, they prepare the liver in advance — building a hospitable environment before they even arrive.

Key Findings from Kanazawa University

A Step-by-Step Metastatic Mechanism

The Kanazawa University team outlined a clear, step-by-step cascade leading to liver metastasis:

• Tumor cells secrete Wnt ligands, which activate nearby stromal fibroblasts.
• Wnt and TGF-β signaling cooperate to convert fibroblasts into cancer-associated fibroblasts (CAFs).
• CAFs express Has2, producing hyaluronan that accumulates at metastatic sites.
• Hyaluronan deposition creates a supportive niche, enabling cancer cells to survive and grow in the liver.

This detailed, mechanistic picture is a significant advance. Previously, researchers understood that gastric cancer spread — but not precisely how it prepared distant tissues for colonization.

Published in Nature Communications

The study — authored by Yuichiro Furutani, Hiroko Oshima, Masanobu Oshima, and colleagues — was published online on February 14, 2026, in Nature Communications (DOI: 10.1038/s41467-026-69470-5). It was supported by Grants-in-Aid for Scientific Research from Japan’s Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Japan Agency for Medical Research and Development (AMED).

Promising Therapeutic Strategies Ahead

Targeting the Tumor Microenvironment

This research opens several exciting therapeutic directions. Rather than targeting only the cancer cell itself, future treatments could aim to disrupt the metastatic niche. Specific strategies suggested by the findings include:

• Blocking Wnt ligand secretion from tumor cells to prevent fibroblast activation.
• Inhibiting Has2 expression to reduce hyaluronan production at metastatic sites.
• Disrupting metastatic niche formation before cancer cells colonize distant organs.

These approaches represent a shift in strategy. Instead of fighting cancer cells after they have already colonized the liver, physicians could potentially prevent the niche from forming in the first place.

Validating Findings in Human Tumors

Importantly, the current research relies on mouse and organoid models. Therefore, future studies will focus on validating these mechanisms in human metastatic tumors. Additionally, researchers plan to explore targeted therapeutic interventions aimed at the tumor microenvironment. The road to clinical application still requires further work — but the scientific foundation is now firmly established.

Why This Research Matters Globally

Gastric cancer remains one of the top causes of cancer-related death worldwide. It spreads readily to the liver and other organs, often before diagnosis. Moreover, because metastatic gastric cancer is notoriously difficult to treat, identifying new targets is urgent.

As Oshima stated: metastasis is driven not only by cancer cells themselves, but by how they reshape surrounding tissue. This insight fundamentally changes the way scientists and clinicians must think about gastric cancer progression. By focusing on the microenvironment — not just the tumor — researchers can develop smarter, more precise therapies.

Additionally, this study highlights the broader importance of ligand-dependent Wnt signaling in tumor-stroma interactions. Thus, the implications extend beyond stomach cancer. Similar mechanisms may operate in other cancers where Wnt signaling plays a role.